Loading…
Bluejay Diagnostics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in BJDX.
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $2.67 | $19.48 | $1,952.00 | $12,160.00 | $81,920.00 | |
| P/S | — | — | — | — | 31.2x | — |
| P/B | 1.1x | 0.4x | 1.3x | 1.1x | 0.7x | 2.5x |
| EPS | -$15.25 | -$456.75 | -$14,525.92 | -$14,752.00 | -$13,120.00 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BDRXBiodexa Pharmaceuticals Plc | $0.87 | — | 0.0x | — | -64.72% | $893.33K |
| PFSAProfusa, Inc. | $1.69 | — | — | — | — | $1.02M |
| NIVFNewGenIvf Group Ltd | $0.34 | 0.0x | 0.0x | — | 79.40% | $833.53K |
| VTAKCatheter Precision, Inc. | $0.20 |
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Company description provided by Yahoo Finance.
| Profit margin | — | — | — | — | -3733.11% | — |
| ROE | -114.61% | -114.61% | -134.70% | -343.85% | -80.55% | -17.11% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.0x |
| — |
| -111.35% |
| $724.42K |
| CDTCDT Equity Inc. | $1.69 | — | 0.0x | — | -69.68% | $1.33M |
| SXTCChina SXT Pharmaceuticals, Inc. | $3.00 | — | 0.1x | — | -27.49% | $1.6M |